Why the study?
Does dexrazoxane prevent cardiomyopathy in anthracycline-treated pediatric cancer patients without diminishing anti-tumor activity?
Does dexrazoxane prevent cardiomyopathy in anthracycline-treated pediatric cancer patients without diminishing anti-tumor activity?
This review highlights the need for better understanding of dexrazoxane pharmacokinetics and optimal administration schedules to safely prevent anthracycline-induced cardiomyopathy in pediatric cancer patients.
Optimal pediatric dexrazoxane dosing lacks pharmacokinetic validation; this leaves open ideal schedules for safe cardioprotection.
Anthracyclines play a major role in chemotherapeutic regimens for a variety of childhood cancers, but produce dose-related cardiotoxicity. Dexrazoxane, a chelating agent that binds iron intracellularly, has been cautiously included in anthracycline-based regimens. Our understanding of anthracycline and dexrazoxane pharmacokinetics in children is very limited. In addition, the administration schedule used for adults (bolus dexrazoxane prior to bolus anthracycline) may not be the best to attain both short- and long-term cardioprotection. Dexrazoxane could diminish the anti-tumor activity of and/or increase toxicities from anthracyclines. Pediatric oncologists must be assured this intervention does not diminish the success in curing children with cancer.
No takes yet. Share an insight, caveat, or question.
Barry Anderson (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: